Calcitonin Gene-Related Peptide (CGRP) Inhibitors: Critical Driver Shaping the Increasing Prevalence Of Migraine Fueling The Growth Of The Market Due To Increasing Stress Levels And Improved Treatment Options Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for calcitonin gene-related peptide (CGRP) inhibitors has seen robust growth in the past few years. The market is expected to expand from $2.87 billion in 2024 to $3.14 billion in 2025, with a compound annual growth rate (CAGR) of 9.6%. This increase during the historic period can be credited to amplified investment in research and development, the endorsement of new drugs, growing preference for non-opioid analgesics, and an intensified emphasis on tailor-made medicine.

Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Size Forecast: What's the Projected Valuation by 2029?
The market for calcitonin gene-related peptide (CGRP) inhibitors is predicted to experience significant expansion in the coming years, reaching an estimated $4.58 billion by 2029 with a compound annual growth rate (CAGR) of 9.9%. This growth during the forecast period is largely due to the increasing incidence of migraine, the wider acceptance of preventative treatments for migraine, enhanced patient knowledge, and the growth of healthcare spending. Future trends in this period are expected to include advancements in drug formulation technology, the incorporation of digital health instruments, advancements in precision medicine, and technological progress in biosimilars.

View the full report here:
https://www.thebusinessresearchcompany.com/report/calcitonin-gene-related-peptide-cgrp-inhibitors-global-market-report

What Are the Drivers Transforming the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
The rising instances of migraines are anticipated to boost the calcitonin gene-related peptide (CGRP) inhibitors market's expansion in the future. Migraines are severe headaches that often cause pulsating pain, typically concentrated on one side of the head. They are typically associated with nausea, vomiting, and an increased sensitivity to light and sound. The escalating occurrence of migraines can be attributed to elevated stress levels, as constant stress triggers neural pathways. Calcitonin gene-related peptide (CGRP) inhibitors play a key role in the management of migraines, delivering a specific preventative function compatible with both acute and chronic care plans. They mitigate both the frequency and intensity of headaches by effectively blocking CGRP receptors, enhancing patient wellness and daily life activity. For example, in January 2023, a report by the National Library of Medicine, a health information institution based in the US, mentions that the worldwide occurrence of migraines ranges from 14 to 15%, accounting for 4.9% of the global disease burden. Thus, the escalating frequency of migraines is fueling the expansion of the calcitonin gene-related peptide (CGRP) inhibitors market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24182&type=smp

Which Emerging Trends Are Transforming the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market in 2025?
Leading enterprises in the calcitonin gene-related peptide (CGRP) inhibitors sector are prioritizing the creation of innovative products to obtain approvals such as calcitonin gene-related peptide (CGRP) receptor antagonists, which improve the effectiveness of migraine treatments. They are also focused on broadening therapeutic applications as well as providing more user-friendly administration options such as oral and intranasal formulations. A calcitonin gene-related peptide (CGRP) receptor antagonist is a medication designed to stop the activity of the calcitonin gene-related peptide (CGRP) receptor, which in turn prevents migraine-related pain signaling. For example, in April 2023, the U.S. Food and Drug Administration (FDA) granted approval to the American biotech firm AbbVie Inc. for QULIPTA (atogepant), a treatment for chronic migraines in adults. QULIPTA, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, functions by blocking the CGRP receptors that play a major role in migraine pathophysiology, thereby aiding the prevention of migraine attacks.

Which Segments in the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market Offer the Most Profit Potential?
The calcitonin gene-related peptide (cgrp) inhibitors market covered in this report is segmented -

1) By Type Of Inhibitor: Monoclonal Antibodies, Small Molecules, Peptides
2) By Mechanism Of Action: Anti-Calcitonin Gene-Related Peptide (CGRP) Ligand, Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonist
3) By Route of Administration: Oral, Nasal, Intravenous
4) By Treatment: Preventive Migraine Treatment, Acute Migraine Treatment
5) By End User: Hospitals, Specialty Clinics, Mail Order Pharmacies, Retail Pharmacies

Subsegments:
1) By Monoclonal Antibodies: Erenumab (Aimovig), Eptinezumab (Vyepti), Fremanezumab (Ajovy), Galcanezumab (Emgality)
2) By Small Molecules: Ubrogepant, Rimegepant, Atogepant, Zavegepant
3) By Peptides: Calcitonin Gene-Related Peptide (CGRP) Antagonist Peptides, Modified Calcitonin Gene-Related Peptide (CGRP) Analogs, Intranasal Peptide Formulations, Peptide-Based Delivery Systems

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=24182&type=smp

Which Firms Dominate the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market by Market Share and Revenue in 2025?
Major companies operating in the calcitonin gene-related peptide (CGRP) inhibitors market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Otsuka Holdings Co. Ltd., Teva Pharmaceutical Industries Ltd., H. Lundbeck A/S, Kissei Pharmaceutical Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., Shin Nippon Biomedical Laboratories Ltd., Sosei Group Corporation, Nuvie Bio Inc., Vaxxinity Inc., Acherx LLC, AfaSci Inc.

Which Regions Offer the Highest Growth Potential in the Calcitonin Gene-Related Peptide (CGRP) Inhibitors Market?
North America was the largest region in the calcitonin gene-related peptide (CGRP) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the calcitonin gene-related peptide (CGRP) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24182

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.